将由VITEK®2产生的来自北美和拉丁美洲的488例肠杆菌的VITEK®2AESβ-内酰胺表型与通过全基因组测序(WGS)提供的抗性基因型进行比较。AES提供了447个(91.6%)分离株的表型报告,包括含有碳青霉烯酶的分离株(195;43.6%),ESBLs(103;23.0%)和可转移AmpC(tAmpC;28;6.3%)基因,以及野生型分离株(WT;121;27.1%)。总的来说,AES报告对433/447(96.9%)个分离株准确.AES准确地报告了碳青霉烯酶,ESBL,和tAmpC表型为93.7%,93.7%,和98.4%的分离株,分别,敏感性/特异性分别为96.4%/91.7%,98.1%/92.4%,82.1%/99.5%,和100%/98.8%。14株携带碳青霉烯酶的分离株(共7株;3KPC,2MBL,2OXA-48-like),ESBL(2),和tAmpC编码基因(5)未通过AES正确鉴定。AES表型报告迅速检测到肠杆菌中的耐药机制,可以显着帮助未来的抗菌药物管理计划和患者护理。
The VITEK®2 AES β-lactam phenotypes of 488 Enterobacterales from North and Latin America generated by the VITEK®2 were compared to the resistance genotypes provided by whole genome sequencing (WGS). The AES provided phenotypic reports for 447 (91.6 %) isolates, including isolates harbouring carbapenemases (195; 43.6 %), ESBLs (103; 23.0 %) and transferable AmpCs (tAmpC; 28; 6.3 %) genes, as well as wildtype isolates (WT; 121; 27.1 %). Overall, the AES report was accurate for 433/447 (96.9 %) isolates. The AES accurately reported
carbapenemase, ESBL, and tAmpC phenotypes for 93.7 %, 93.7 %, and 98.4 % of isolates, respectively, and sensitivity/specificity rates were 96.4 %/91.7 %, 98.1 %/92.4 %, 82.1 %/99.5 %, and 100 %/98.8 %. 14 isolates carrying
carbapenemase (7 total; 3 KPC, 2 MBL, 2 OXA-48-like), ESBL (2), and tAmpC-encoding genes (5) were not correctly identified by AES. The AES phenotypic report detected resistance mechanisms among Enterobacterales rapidly and could significantly aid future antimicrobial stewardship initiatives and patient care.